News

A new compound developed by researchers at MUSC Hollings Cancer Center shows promise in overcoming chemotherapy resistance in triple-negative breast cancer.

Howard Hughes Medical Institute chooses MUSC student, adviser for Gilliam Fellows program based on research, commitment to equity and inclusion.

The CREW program encourages early-career women in science to become entrepreneurs.

Too many lung cancer patients don't get all the biomarker testing they should have before beginning treatment. Dr. Adam Fox wants to change that.

A Hollings immunologist will use an American Cancer Society Research Scholar Grant to study ways to make colorectal cancer more susceptible to immunotherapy.

An MUSC Hollings Cancer Center team describes how the bacteria Porphyromonas gingivalis connects to chemotherapy resistance.

Polyploid giant cancer cells, which are monstrously oversized and contain multiple nuclei, could be culprits in disease recurrence after cancer therapy.

A new study from Hollings researchers suggests a dual approach for targeting pancreatic cancer.

External evaluation of MUSC’s telestroke program confirms that stroke center certification and stroke coordinators improve stroke-care metrics.

A new dedicated phase I clinical trials unit at Hollings means more and different types of clinical trials will be available to cancer patients.